Head of Non-Standard Investments at FinTrust, Vincent C. du Vigneaud, Joins Advisory Board of Xcelerate, Inc.

Rhea-AI Summary

Xcelerate, Inc. (OTC: XCRT) announced on April 27, 2021, that Vincent C. du Vigneaud has joined its Advisory Board. With over 25 years of experience in financial analysis and capital structure, du Vigneaud is currently the Head of Non-Standard Investments at FinTrust Capital Advisors, which manages over $1.5 billion. His expertise in regulatory issues and business combinations is expected to support Xcelerate's development plans. The company aims to innovate acquisitions in medical technology and enhance clinical applications.

Positive

• Vincent C. du Vigneaud's extensive experience in financial analysis and capital structure may strengthen Xcelerate's development efforts.
• His knowledge of regulatory issues could provide strategic advantages in business combinations and capital funding programs.

Negative

• None.

MAULDIN, S.C., April 27, 2021 /PRNewswire/ -- Xcelerate, Inc (OTC: "XCRT"), a rapidly emerging leader in assembling and developing early-stage medical technology today announced  Vincent C. du Vigneaud has joined its Advisory Board.

du Vigneaud currently serves as Portfolio Manager/Analyst/ Trader and Head of Non-Standard Investments FinTrust Capital Advisors in Greenville, SC. FinTrust is an RIA and Investment Management firm with over $1.5 billion in client assets. Prior to joining FinTrust Vincent held various trading / operations positions with several fund management firms and co-founded SuNOVA Capital and Thesis Fund Management, both New York-based hedge funds.

"Vincent brings another invaluable skill set to our Advisory Board," said Michael O'Shea, Xcelerate' s CEO. "His 25 years of experience in financial analysis and capital structure, along with his knowledge of regulatory issues will be a tremendous aide in the next phase of our development plan which is to analyze business combinations and develop capital funding programs.  duVigneaud also worked as an analyst and trader at Olayan America, the Family Office for the Olayan Family (over $10 billion net worth), said O'Shea.

About Xcelerate

Xcelerate is a company seeking innovative acquisitions within the patent/engineering world and focused on joining early-stage medical technology companies in a setting that is a controlled clinical care where these new developments can be trailed, tested and applied.

To interview either du Vigneaud or O'Shea, contact Justin Baronoff at 561-750-9800; Justin@transmediagroup.com.

SAFE HARBOR

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

View original content:http://www.prnewswire.com/news-releases/head-of-non-standard-investments-at-fintrust-vincent-c-du-vigneaud-joins-advisory-board-of-xcelerate-inc-301277615.html

SOURCE Xcelerate, Inc.

FAQ

Who is Vincent C. du Vigneaud and what is his role at Xcelerate?

Vincent C. du Vigneaud is a financial expert who has joined Xcelerate's Advisory Board to assist with financial analysis and capital structure.

What is Xcelerate's focus in the medical technology field?

Xcelerate is focused on innovative acquisitions within the medical technology sector, particularly early-stage companies.

How might du Vigneaud's experience impact Xcelerate's business strategy?

His 25 years of experience in financial analysis and knowledge of regulatory issues could enhance Xcelerate's capital funding and business combination strategies.

What does the Advisory Board do at Xcelerate?

The Advisory Board provides strategic guidance and expertise to support the company's development plans and business strategies.